Long Island Operations began manufacturing hand sanitizer at the
'It is the first time we have manufactured hand sanitizer. With the hard work and dedication of all of the associates, we quickly put all of the pieces in place to make this happen,' said
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such 'potential,' 'can,' 'will,' 'plan,' 'expect,' 'anticipate,' 'look forward,' 'move forward,' 'believe,' 'committed,' 'investigational,' 'pipeline,' 'launch,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products, or regarding the transaction described in this press release. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that our US generic oral solids and dermatology businesses will be successful in the future. Neither can there be any guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that, if approved, such products will be approved for all indications included in the reference product's label, or commercially successful in the future. In particular, our expectations regarding such businesses and products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit
About Novartis
Located in
Novartis and Novartis US is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartisnews and @NovartisUS at https://twitter.com/NovartisUS
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com
Novartis Media Relations
E-mail: media.relations@novartis.com
Head,
+1 646 438 4335
eric.althoff@novartis.com
+49 174 244 9501 (mobile)
chris.lewis@sandoz.com
Director, US Media Relations
+1 862-217-3976
jamie.bennett@novartis.com
+1 201 354 0279 (mobile)
leslie.pott@sandoz.com
(C) 2020 Electronic News Publishing, source